Concepedia

Author

Paul Elvin

AstraZeneca (United Kingdom)

Also Known As

P A Elvin, P ELVIN, P Elvin, P. Elvin, Paul Elvin

116

Publications

1.9K

Citations

24

H-Index

45

Concepts

All Affiliations

AstraZeneca (United Kingdom)InsermEast Cheshire NHS TrustInstitut CurieInstitute of Cancer Research
PE

About

Paul Elvin is an author at AstraZeneca (United Kingdom) specializing in medicine, cancer research, and tumor biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

12

14

677

2

Cell Biology

7

7

270

3

Natural Sciences

1

1

11

4

Biochemistry

1

1

11

5

Biomedical Engineering

1

1

24

Paul Elvin

×

34

Publications

1.8K

Citations

24

H-Index

YearCitations

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

Tim P. Green, Mike Fennell, Robin Whittaker,

Molecular Oncology

2009

254

Regional copy number–independent deregulation of transcription in cancer

Nicolas Stransky, Céline Vallot, Fabien Reyal,

Nature Genetics

2006

253

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i> -Mutated Breast and Gynecologic Cancers

Udai Banerji, Emma Dean, José Alejandro Pérez Fidalgo,

Clinical Cancer Research

2017

139

Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors

José Baselga, Andrés Cervantes, Erika Martinelli,

Clinical Cancer Research

2010

108

Isolation of cDNA clones using yeast artificial chromosome probes

Paul Elvin, G. Slynn, D. N. Black,

Nucleic Acids Research

1990

80

Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function

Amanda G. Ammer, Laura C. Kelley, Karen E. Hayes,

Journal of Cancer Science & Therapy

2009

79

Visualizing Chromosomes as Transcriptome Correlation Maps: Evidence of Chromosomal Domains Containing Co-expressed Genes—A Study of 130 Invasive Ductal Breast Carcinomas

Fabien Reyal, Nicolas Stransky, Isabelle Bernard‐Pierrot,

Cancer Research

2005

76

Plasminogen activator inhibitor type 2 in breast cancer

Catherine Duggan, Susan Kennedy, MD Kramer,

British Journal of Cancer

1997

72

Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer

Hyun-Jin Nam, Seock‐Ah Im, Do‐Youn Oh,

Molecular Cancer Therapeutics

2012

67

Gene Array and Fluorescence <i>In situ</i> Hybridization Biomarkers of Activity of Saracatinib (AZD0530), a Src Inhibitor, in a Preclinical Model of Colorectal Cancer

John J. Arcaroli, Basel M. Touban, Aik Choon Tan,

Clinical Cancer Research

2010

59

Page 1